The prediction of recurrence and survival of patients with Dukes’ B colorectal cancer after curative resection with immunohistochemical detection of Survivin and Livin expressions

Article

Abstract

Objective

To detect the expressions of Survivin and Livin in Dukes’ B colorectal cancer tissues and analyze the prognosis after curative resection.

Methods

The expressions of Survivin and Livin were evaluated immunohistochemically in Dukes’ B colorectal cancer specimens from 81 patients after curative resection of the tumor. Their correlations to clinical characters and survival were also explored.

Results

The positive rates of Survivin and Livin in colorectal cancer tissues were significantly higher than those in normal colorectal tissues (58.0% vs. 16.7% and 45.7% vs. 8.3% respectively, P < 0.05). The expressions of Survivin and Livin were not related to gender, tumor site, primary size, T stage, pathologic category, and degree of differentiation (P > 0.05), and no relationship was found between the expressions of Survivin and Livin (P > 0.05). The expression rate of Survivin in patients older than 50 years was higher than that in patients younger than 50 years (70.6% vs. 36.7%, P < 0.05). Both Survivin and Livin were related to recurrence and/or metastasis (P = 0.02 and P = 0.001, respectively), and shorter survival (P = 0.039 and P = 0.001, respectively). Cox multivariate analysis showed T4 and positive Livin expression were independent prognostic factors (P = 0.002 and P = 0.047, respectively).

Conclusion

Survivin and Livin are over-expressed in Dukes’ B colorectal cancer tissues and are positively related to recurrence and/or metastasis and poor prognosis after curative resection of the tumor.

Key words

inhibitor of apoptosis proteins colorectal cancer apoptosis prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry, 2001, 40: 1117–1123.PubMedCrossRefGoogle Scholar
  2. 2.
    Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem, 2001, 276: 3238–3246.PubMedCrossRefGoogle Scholar
  3. 3.
    Song YC, Wan DS, Pan ZZ, et al. The expression and clinicalbiological significance of Survivin in Duke’s C stage colorectal cancer. Chin Clin Oncol (Chinese), 2005, 32: 979–983.Google Scholar
  4. 4.
    Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res, 1995, 55: 1811–1816.PubMedGoogle Scholar
  5. 5.
    Yang D, Zhu YQ, Qi J. Expressions and clinical significance of Survivin gene and PTEN protein in colorectal adenocarcinoma. Chin J Cancer (Chinese), 2004, 23: 306–309.Google Scholar
  6. 6.
    Yang J, Liu FX, Yan XC, et al. Clinical significance of Survivin expression in colorectal cancer and its relationship with cell apoptosis and angiogenesis. Chin J Cancer (Chinese), 2005, 24: 116–120.Google Scholar
  7. 7.
    Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother, 2004, 53: 770–776.PubMedCrossRefGoogle Scholar
  8. 8.
    Xiang Y, Yao H, Wang S, et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope, 2006, 116: 126–130.PubMedCrossRefGoogle Scholar
  9. 9.
    Kim DK, Alvarado CS, Abramowsky CR, et al. Expression of inhibitor-of-apoptosis protein (IAP) Livin by neuroblastoma cells: correlation with prognostic factors and outcome. Pediatr Dev Pathol, 2005, 8: 621–629.PubMedCrossRefGoogle Scholar
  10. 10.
    Gong J, Chen N, Zhou Q, et al. Melanoma inhibitor of apoptosis protein is expressed differentially in melanoma and melanocytic naevus, but similarly in primary and metastatic melanomas. J Clin Pathol, 2005, 58: 1081–1085.PubMedCrossRefGoogle Scholar
  11. 11.
    Yagihashi A, Asanuma K, Tsuji N, et al. Detection of anti-Livin antibody in gastrointestinal cancer patients. Clin Chem, 2003, 49: 1206–1208.PubMedCrossRefGoogle Scholar
  12. 12.
    Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett, 2001, 495: 56–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Benson AB 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 2004, 22: 3408–3419.PubMedCrossRefGoogle Scholar
  14. 14.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 2003, 349: 247–257.PubMedCrossRefGoogle Scholar
  15. 15.
    Gazzaniga P, Gradilone A, Giuliani L, et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol, 2003, 14: 85–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Jaattela M. Escaping cell death: survival proteins in cancer. Exp Cell Res, 1999, 248: 30–43.PubMedCrossRefGoogle Scholar

Copyright information

© Editorial Office of Chinese-German Journal of Clinical Oncology 2008

Authors and Affiliations

  1. 1.Department of OncologyThe First Affiliated Hospital, Nanchang UniversityNanchangChina
  2. 2.Department of Blood TransfusionThe First Affiliated Hospital, Nanchang UniversityNanchangChina
  3. 3.Department of Medical Oncology, Cancer CenterSun Yat-sen UniversityGuangzhouChina

Personalised recommendations